Prior to joining TPG in 2004, Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As Vice President of Genomics at Millennium, Geoff was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project.
Dr. Duyk holds a PhD and MD from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from HHMI.
Dr. Duyk serves on the Board of Directors of Replidyne, Macrogenics, Aerie, FoldRx, Amyris, Galleon, Moksha8, ShangPharma, Agria, Elevance and JCR.
Dr. Duyk is a council member of the National Human Genome Research Institute at NIH. He also serves on the Scientific Advisory Boards of the NHGRI DNA Sequencing Advisory Panel, Chair of the KOMP (Global Mouse TKO project), ESC (Expressed Sequenced Consortium), Co-Chair Advisory Panel Cancer Genome Anatomy Project, Program in Genomics Applications (NHBLI); the Bioethics Advisory Group at Case Western Reserve University; the Spinal Muscular Atrophy Foundation; WIL Laboratories; VLST; and FoldRx.
Dr. Duyk is a former member of the Board of Directors of Avidia, recently sold to Amgen.
Robert is a Partner with Naxos UK and prior to joining Naxos, he was a Managing Director in charge of the London office of Allianz Capital Partners GmbH and instrumental in the development of its private equity, mezzanine and infrastructure activities. Prior to this, Robert was part of the founding team of Nikko Principal Investments Limited and was part of the original Nomura Principal Finance Group. Robert has an MBA from the London Business School, more than 15 years of private equity experience and has board level responsibility with several companies internationally.
Bill leads the operational effectiveness practice within the Growth Platform and works with portfolio companies on growth initiatives, sales force effectiveness, process improvement, supply chain management, asset utilization, and human capital productivity. He works primarily in the consumer products, retail, healthcare, industrial and business services sectors.
Prior to joining TPG in 2011, Mr. Schwartz was EVP, TBM Consulting Group from 1991 to 2011. Bill was trained in LeanSigma Manufacturing, Six Sigma and continuous improvement principles, and worked closely with the former Toyota Production System pioneers from Shingijutsu, Ltd. Bill led the business development effort for TBM as the company grew at 30 percent CAGR for more than 15 years. During his tenure with TBM, Bill also founded and was President of TBM Holdings, sponsoring the acquisition of three companies in the material handling industry.
Formerly, Bill was with Howell Management Company and was Vice President, Sales & Marketing for Medallic Art Company. He started his career as a Marketing Representative for IBM Corporation.
He earned a BA in mathematics from Colgate University and an MBA from the Stern School of Business, New York University.
Carole is the Founding Director of Naxos UK. A member of the bar of New York and of Paris, she has practiced law in the US and France, specializing in mergers and acquisitions. Thereafter, she has spent fifteen years in various senior management roles in food and drinks and agricultural processing, including as Chairman of the Amylum Group and Vice Chairman and Director of Tate & Lyle. She also holds a number of independent board positions, including Aviva plc, Louis Delhaize, Eutelsat and Sanofi-Aventis.
Director Tan Kong Han was appointed as President and Chief Operating Officer of Genting Berhad in 2007. Genting Berhad is the holding company of the Genting Group which has more than 58,000 employees, 4,500 hectares of prime resort land and about 133,000 hectares of plantation land. The Genting Group is one of Asia's most dynamic conglomerates and is involved in leisure & hospitality, power generation, oil palm plantations, property development, biotechnology, and oil & gas business activities.
He was previously the Group Chief Operating Officer of Tanjong Public Limited Company, which is an investment holding company of a group of subsidiaries involved in Power Generation, Leisure and Property Investment. Tan Kong Han also has more than 13 years' working experience in investment banking and is a qualified Barrister at Law, Lincoln's Inn. He holds an MA from the University of Cambridge.